Showing 1161-1170 of 7167 results for "".
Lashing Out: A New Direction in Lash Treatment
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/lashing-out-a-new-direction-in-lash-treatment/20743/New eyelash ptosis treatment means no more lash curlers.New Advancements in Microneedle Resurfacing
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-advancements-in-microneedle-resurfacing/21354/Microneedle resurfacing has quickly become one of the most in-demand aesthetic procedures, likely due to its strong results, quick healing times, and cost-effectiveness.Taking the Pulse of Hydroquinone Therapy: A Plea for Caution
https://practicaldermatology.com/topics/general-topics/taking-the-pulse-of-hydroquinone-therapy-a-plea-for-caution/22946/Pulse therapy under physician supervision can reduce long-term exposure and help reduce the risk of untoward effects of hydroquinone therapy.Finding Joy in Dermatology
https://practicaldermatology.com/issues/october-2025/finding-joy-in-dermatology/39751/Go out there and find your joy. Do more of it. And appreciate every second of it.Telephone Mystery Shopping and Converting New Patients
https://practicaldermatology.com/issues/april-2025/telephone-mystery-shopping-and-converting-new-patients/35621/Even with today’s market focused on online digital marketing, a practice’s biggest revenue source opportunity still seems to be the phones. The first interaction most new patients have with a practice is on the phone, which used to be about 99% of the time; now, we believe it is about 80%.Dermatologists Push Back on Wall Street Journal Characterization
https://practicaldermatology.com/issues/january-february-2025/dermatologists-push-back-on-wsj-characterization/32900/Four-day workweeks, double the salary of some colleagues and no emails at night—those were the reasons a Wall Street Journal article concluded that medical residency applications for dermatology slots are up 50% over the past 5 years. Practical Dermatology reached out to dermatologists to get theirTaking the Leap Into Private Practice
https://practicaldermatology.com/programs/practical-dermatology/taking-the-leap-into-private-practice/24042/Practice is hard. Private practice is even harder.Best Practices for the 2023 Biologic Coordinator
https://practicaldermatology.com/columns/biologic-coordinator/best-practices-for-the-2023-biologic-coordinator/23839/Tips for preparing for the new year to ensure the needs of biologic patients are being met.Pay it Backwards
https://practicaldermatology.com/topics/practice-management/pay-it-backwards/20640/Why do women in dermatology earn only 83 percent of what men earn?Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects s